179 related articles for article (PubMed ID: 22875697)
21. Tracking the intracellular drug release from graphene oxide using surface-enhanced Raman spectroscopy.
Huang J; Zong C; Shen H; Cao Y; Ren B; Zhang Z
Nanoscale; 2013 Nov; 5(21):10591-8. PubMed ID: 24057012
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro.
Khdair A; Handa H; Mao G; Panyam J
Eur J Pharm Biopharm; 2009 Feb; 71(2):214-22. PubMed ID: 18796331
[TBL] [Abstract][Full Text] [Related]
23. Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells.
Cui X; Zhou S; Xu H; Zhao T; Liu A; Guo X; Wang F
Anticancer Drugs; 2009 Oct; 20(9):800-6. PubMed ID: 19606017
[TBL] [Abstract][Full Text] [Related]
24. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro.
Wang Y; Chen L; Ding Y; Yan W
Int J Pharm; 2012 Jan; 422(1-2):409-17. PubMed ID: 22037443
[TBL] [Abstract][Full Text] [Related]
25. Layer-by-layer assembly of graphene oxide on thermosensitive liposomes for photo-chemotherapy.
Hashemi M; Omidi M; Muralidharan B; Tayebi L; Herpin MJ; Mohagheghi MA; Mohammadi J; Smyth HDC; Milner TE
Acta Biomater; 2018 Jan; 65():376-392. PubMed ID: 29109030
[TBL] [Abstract][Full Text] [Related]
26. A tumor targeted near-infrared light-controlled nanocomposite to combat with multidrug resistance of cancer.
Wang M; Wu J; Li Y; Li F; Hu X; Wang G; Han M; Ling D; Gao J
J Control Release; 2018 Oct; 288():34-44. PubMed ID: 30171977
[TBL] [Abstract][Full Text] [Related]
27. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
Gao HD; Sun JZ; Bi DS; Ma R
Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
[TBL] [Abstract][Full Text] [Related]
28. [Up-regulation of c-myc expression in MCF-7/Adr human breast cancer cells and its association with resistance against doxorubicin].
Chen J; Yuan YW; Zhang JR; Zhou DY
Di Yi Jun Yi Da Xue Xue Bao; 2002 Feb; 22(2):124-6. PubMed ID: 12390804
[TBL] [Abstract][Full Text] [Related]
29. Multifunctional nanocomposite based on graphene oxide for in vitro hepatocarcinoma diagnosis and treatment.
Shen AJ; Li DL; Cai XJ; Dong CY; Dong HQ; Wen HY; Dai GH; Wang PJ; Li YY
J Biomed Mater Res A; 2012 Sep; 100(9):2499-506. PubMed ID: 22623284
[TBL] [Abstract][Full Text] [Related]
30. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles.
Gao Y; Chen Y; Ji X; He X; Yin Q; Zhang Z; Shi J; Li Y
ACS Nano; 2011 Dec; 5(12):9788-98. PubMed ID: 22070571
[TBL] [Abstract][Full Text] [Related]
31. Graphene oxide based magnetic nanocomposites for efficient treatment of breast cancer.
Chaudhari NS; Pandey AP; Patil PO; Tekade AR; Bari SB; Deshmukh PK
Mater Sci Eng C Mater Biol Appl; 2014 Apr; 37():278-85. PubMed ID: 24582250
[TBL] [Abstract][Full Text] [Related]
32. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells.
Mussi SV; Sawant R; Perche F; Oliveira MC; Azevedo RB; Ferreira LA; Torchilin VP
Pharm Res; 2014 Aug; 31(8):1882-92. PubMed ID: 24522814
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
34. A dynamic study on reversal of multidrug resistance by ginsenoside Rh₂ in adriamycin-resistant human breast cancer MCF-7 cells.
Zhou B; Xiao X; Xu L; Zhu L; Tan L; Tang H; Zhang Y; Xie Q; Yao S
Talanta; 2012 Jan; 88():345-51. PubMed ID: 22265509
[TBL] [Abstract][Full Text] [Related]
35. Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
Lopez-Barcons LA; Polo D; Llorens A; Reig F; Fabra A
Oncol Rep; 2005 Nov; 14(5):1337-43. PubMed ID: 16211306
[TBL] [Abstract][Full Text] [Related]
36. Controlled release of doxorubicin from graphene oxide based charge-reversal nanocarrier.
Zhou T; Zhou X; Xing D
Biomaterials; 2014 Apr; 35(13):4185-94. PubMed ID: 24513318
[TBL] [Abstract][Full Text] [Related]
37. A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
Shi R; Li W; Zhang X; Zhang Y; Peng H; Xie Y; Fan D; Liu R; Liu X; Xiong D
Eur J Pharmacol; 2011 Nov; 669(1-3):38-44. PubMed ID: 21871878
[TBL] [Abstract][Full Text] [Related]
38. Carboxymethyl chitosan-mediated synthesis of hyaluronic acid-targeted graphene oxide for cancer drug delivery.
Yang H; Bremner DH; Tao L; Li H; Hu J; Zhu L
Carbohydr Polym; 2016 Jan; 135():72-8. PubMed ID: 26453853
[TBL] [Abstract][Full Text] [Related]
39. [Screening the differential expression of adriamycin-resistance related genes of breast cancer by cDNA microarray].
Peng H; Yang HW; Song LW; Zhou Z
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(25):1745-8. PubMed ID: 19862977
[TBL] [Abstract][Full Text] [Related]
40. FK506 completely inhibits adriamycin efflux in the adriamycin-resistant strain of Ehrlich ascites tumor cells.
Asaumi J; Kawasaki S; Nishikawa K; Kuroda M; Takeda Y; Hiraki Y
Anticancer Res; 1996; 16(1):247-50. PubMed ID: 8615615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
